drugset / Trial / NCT00855920

Study Utilizing Rilonacept in Gout Exacerbations

NCT00855920

Phase 3 Completed 225 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.

Timeline

Start
2009-03
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Indomethacin Small molecule 25 mg Oral
Comparator Rilonacept Protein / enzyme biologic 320 mg Subcutaneous

Indications